Home - Melanoma Research Alliance

7200 Miles for 7200 Lives Lost: Cycling and Community Building After a Melanoma Diagnosis

Last year in the US, there were an estimated 7,180 deaths from melanoma. For melanoma patient and competitive cyclist Bill Evans, this number is on his mind every single day. Two years into his own journey with advanced melanoma, Bill is raising awareness and funds for melanoma research through cycling, with a goal of completing one mile for every life lost to the disease over the course of a year.
Read More
New Research Says Combination Immunotherapy Should be First-Line Therapy for Patients with BRAF-mutant Melanoma

While all patients with advanced melanoma can be treated with checkpoint immunotherapies, patients with tumors containing the BRAF mutation can also be treated with targeted therapies. However, until now, doctors have had little prospective data to determine which treatment approach should be started first. A new study led by Dr. Michael Atkins provides practice-changing insight.
Read More
From Personal Loss to Professional Service

Since 2009, O’Melveny & Myers (OMM), an internationally recognized law firm founded in 1885, has served as pro bono counsel for the Melanoma Research Alliance. But for OMM Partner Steve Brody, supporting MRA is more than just professional service.
Read More
Full Sails Ahead: Immunotherapy Shows Continued Survival Benefit for Patients Facing Advanced Melanoma

After carefully following patients enrolled in Checkmate 067 over the last 6.5 years, he and the research team determined that 49% of patients treated with Opdivo + Yervoy were alive at 6.5 years and 77% of these patients remained treatment-free. This represents the longest reported median overall survival in a phase 3 melanoma clinical trial – ever.
Read More
Paving a Path for Cancer Vaccines

Although vaccines to prevent COVID-19 have dominated conversations and the news cycle since the start of the pandemic — Dr. Nina Bhardwaj and her team have been busy at work with a different type of vaccine altogether: one to support melanoma treatment and reduce risk of recurrence.
Read More

Find a Clinical Trial
Get Connected

Latest Report
Get Involved
About MRA

What's New

05/11/2022 – The Melanoma Research Alliance Names Dr. Marc Hurlbert as Chief Executive Officer

05/09/2022 – Dr. Gary Deng & The Wellness Principles

04/21/2022 – A Message from the Melanoma Research Alliance

03/18/2022 – MRA Statement on FDA Approval of Relatlimab + Nivolumab for Treatment of Advanced Melanoma

01/26/2022 – MRA Celebrates Approval of Tebentafusp - First Drug for Metastatic Uveal Melanoma

MRA would like to thank our 2022 Scientific Retreat & Patient Forum Sponsors: